.gif) VIARTIS
|
||
|
|
PARKINSON'S DISEASE NEWS
|
|
|
11th October 2009 - New research DUAL LAYER L-DOPA FOR PARKINSON'S DISEASE Clinical Neuropharmacology [2009] 32 (4) : 189-192 (Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.) Complete abstract IPX054,
which is a form of L-dopa, in which there are two layers, has been shown to be
slightly more effective than conventional forms of L-dopa, despite only having
to be taken twice a day instead of throughout the day. L-dopa usually comes in
two different formats : either the immediate release version, which satisfies
the immediate need for
L-dopa, or the controlled
release version, which avoids the excessive effects of L-dopa by spreading out
the effect
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please double click on E-MAIL NOTIFICATION, or e-mail [email protected]. No form of identity is required. E-mail addresses are not used for any other purpose. Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided, as well as links to the complete abstracts and news reports.
|
||
|
|
||
.gif) |
||
| ©2006-2009 Viartis | ||
| 2015-11-10 13:23:48 | ||
| [email protected] | ||
over
time. IPX054 combines the two types of L-dopa, immediate release and controlled
release, in one tablet, in two different layers, aiming to provide the benefits
of both formats. In clinical practice, this ease of administration may offer
improved treatment compliance and effectiveness.
